Angiotensin II receptor antagonists and erectile function

Abstract Objective. To determine the effect of valsartan on the androgen status and erectile function in hypertensive patients. Design and methods. 60 hypertensive patients of 40-65 years of age were included in the study. All patients filled in the questionnaire on aging male symptoms scale and international index of erectile function before and 3 months after the course of antihypertensive therapy. Patients of the first group received angiotensin II receptor antagonist (valsartan) as monotherapy. Valsacor was administered starting from the first 24 hours after destabilization of blood pressure, and the dose was titrated from 80 up to 160 mg/day. Traditional treatment of hypertension including angiotensin converting enzyme inhibitors, calcium antagonists, diuretics and beta-blockers was prescribed to controls. Results. Valsacor treatment reduced the intensity of the symptoms of erectile dysfunction in hypertensive males (by 11,3 against 2,2 % in the control group, p < 0,05). In addition, this therapy led to a decrease in androgen deficiency symptoms (20,2 against 12,1 %, respectively, p < 0,05). Systolic and diastolic blood pressure reduction was comparable in both groups. There was an increase in the number of «dippers» at valsacor treatment, while the number of other categories («over-dipper», «non-dipper», «night-peaker») decreased (p < 0,05). In the control group, circadian blood pressure profile was not changed. Conclusion. Thus, therapy with valsartan normalizes diurnal variations in blood pressure, reduces the symptoms of androgen deficiency and does not contribute to erectile dysfunction.

angiotensin II receptor antagonists, arterial hypertension, erectile function, valsartan

1. United Nations department of economic and social affairs. Population division. World population prospects: the 2000 revision. No. EO1.XII.12. - N.Y.: United Nations, 2001. - P. 277-293. 2.

2.

3. Вёрткин А.Л., Адонина Е.В., Галкин И.В., Стахнев Е.Ю., Скотников А.С. Место блокаторов рецепторов ангиотензина в терапии артериальной гипертензии у пациентов с полипатией // Рус. мед. журн. - 2009. - № 8. - С. 589-595.

4.

5. Wogen J., Kreilick C.A., Livornese R.C. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting // J. Managed Care Pharm. - 2003. - Vol. 9, № 5. - P. 424-429.

6.

7. Weber M.A., Julius S., Kjeldsen S.E., Brunner H.R., Ekman S., Hansson L. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial // Lancet. - 2004. - Vol. 363., № 9426. - P. 2049-2051.

8.

9. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // N. Engl. J. Med. - 2001. - Vol. 345, № 23. - P. 1667-1675.

10.

11. Pfeffer M.A., McMurray J.J.V., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both // N. Engl. J. Med. - 2003. - Vol. 349, № 20. - P. 1893-1906.

12.

13. Neutel J., Weber M., Pool J. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours // Clin. Ther. - 1997. - Vol. 19, № 3. - P. 447-458.

14.

15. Mclnnes G.T. Angiotensin II antagonism in clinical practice: experience with valsartan // J. Cardiovasc. Pharmacol. - 1999. - Vol. 33, Suppl. 1. - P. 29-32.

16.

17. Malacco E., Santonastaso M., Vari N.A. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study // Clin. Ther. - 2004. - Vol. 26, № 6. - P. 855-865.

18.

19. O'Keefe M., Hunt D.K. Assessment and treatment of impotence // Med. Clin. North. Am. - 1995. - Vol. 79, № 2. - P. 415-434.

20.

21. Burchardt M., Burchardt T., Baer L. et al. Hypertension is associated with severe erectile dysfunction // J. Urol. - 2000. - Vol. 164, № 4. - P. 1188-1191.

22.

23. Roth A., Kalter-Leibovici O., Kerbis Y. et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1412 Israeli men // Clin. Cardiol. - 2003. - Vol. 26, № 1. - P. 25-30. 13.

24.

25. Вёрткин А.Л., Пушкарь Д.Ю. Эректильная дисфункция: кардиологические аспекты. - М.: Изд-во «Мед Пресс», 2005. - 144 с.

26.

27. Jackson G. A male cardiovascular sexual health clinic // Int. J. Clin. Pract. - 2002. - Vol. 56, № 9. - P. 631. 15.

28.

29. Küng C.F., Moreau P., Takase H., Lüscher T.F. L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil // Hypertension. - 1995. - Vol. 26, № 5. - P. 744-751.

30.

31. Hale T.M., Okabe H., Heaton J.P., Adams M.A. Antihypertensive drugs induce structural remodeling of the penile vasculature // J. Urol. - 2001. - Vol. 166, № 2. - P. 739-745.

32.

33. Cellek S., Rodrigo J., Lobos E., Fernandez P., Serrano J., Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon // Br. J. Pharmacol. - 1999. - Vol. 128, № 8. - P. 1804-1812.

34.

35. Malacco E., Vari N., Capuano V., Spagnuolo V., Borguino C., Palatini P. A randomized, double-blind, active controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study // Clin. Ther. - 2003. - Vol. 25, № 11. - P. 2765-2780.

36.

37. Shiri R., Koskimäki J., Häkkinen J., Auvinen A., Tammela T.L.J., Hakama M. Cardiovascular drug use and the incidence of erectile dysfunction // Int. J. Impot. Res. - 2007. - Vol. 19, № 2. - P. 208-212.

38.

39. Fogari R., Zoppi A., Corradi L., Mugellini A., Poletti L., Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol // Am. J. Hypert. - 1998. - Vol. 11, № 10. - P. 1244-1247.

40.

41. Caro J., Vidal J., Vicente J. Sexual dysfunction in hypertensive patients treated with losartan // J. Med. Sci. - 2001. - Vol. 321, № 5. - P. 336-341.

42.

43. Kifor I., Williams G.H., Vickers M.A. Tissue angiotensin II as a modulator of erectile dysfunction. Angiotensin peptide content, secretion, and effects in the corpus cavernosum // J. Urol. - 1997. - Vol. 157, № 5. - P. 1920-1925.

44.

45. Goodman-Gruen D., Barrett-Connor E. A prospective study of sex hormone binding globulin and fatal cardiovascular disease in Rancho Bernardo men and women // J. Clin. Endocrinol. Metab. - 1996. - Vol. 81, № 8. - P. 2999-3003.

46.

47. Svartberg J., Jenssen T., Sundsfjord J. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study // Eur. J. Endocrinol. - 2004. - Vol. 150, № 1. - P. 65-71.

48.

49. Ольбинская Л.И., Мартынов А.И., Хапаев Б.А. Мониторирование артериального давления в кардиологии. - М.: Изд-во «Русский врач». - 1998. - 99 с.

50.

51. Pickering T.G. The clinical significance of diurnal blood pressure variations, dippers and nondippers // Circulation. - 1990. - Vol. 81, № 2. - P. 700-702.

52.

53. Kario K., Matsuo T., Kobayashi H. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly patients: advanced silent cerebrovascular damage in extreme dippers // Hypertension. - 1996. - Vol. 27, № 1. - P. 130-135.

54.

55. Кобалава Ж.Д., Котовская Ю.В. Мониторирование артериального давления: методические аспекты и клиническое значение. - М.: Изд-во «Мед Пресс», 1999. - 234 с.

56.

57. Staessen J.A., Bieniaszewski L., O'Brien E. Nocturnal blood pressure fall on ambulatory monitoring in a large international database // Hypertension. - 1997. - Vol. 29, № 1. - P. 30-39.